株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

末梢神経障害性疼痛:パイプライン製品の分析

Peripheral Neuropathic Pain - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 276009
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
末梢神経障害性疼痛:パイプライン製品の分析 Peripheral Neuropathic Pain - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 67 Pages
概要

末梢神経障害性疼痛は組織の損傷に伴って慢性的に疼痛が起きている状態で、アルコール依存症、糖尿病、化学療法、感染症、手術および多発性硬化症などの要因によっても発症します。灼熱痛、刺痛、しびれなどが症状で、非ステロイド系の抗炎症剤、抗けいれん剤、抗うつ剤などが治療に使われます。

当レポートでは、末梢神経障害性疼痛に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

末梢神経障害性疼痛の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

末梢神経障害性疼痛:企業で開発中の治療薬

末梢神経障害性疼痛:大学/機関で研究中の治療薬

末梢神経障害性疼痛:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

末梢神経障害性疼痛:企業で開発中の製品

末梢神経障害性疼痛:大学/機関で研究中の製品

末梢神経障害性疼痛の治療薬開発に従事している企業

  • Achelios Therapeutics, Inc.
  • AnaBios Corporation
  • Chromocell Corporation
  • Eli Lilly and Company
  • GW Pharmaceuticals Plc
  • Nektar Therapeutics
  • Phosphagenics Limited
  • Spherium Biomed S.L.
  • Sunovion Pharmaceuticals Inc.
  • Zynerba Pharmaceuticals, Inc.

末梢神経障害性疼痛:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

末梢神経障害性疼痛:最近のパイプライン動向

末梢神経障害性疼痛:休止中のプロジェクト

末梢神経障害性疼痛:開発が中止された製品

末梢神経障害性疼痛:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8590IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides an overview of the Peripheral Neuropathic Pain (Central Nervous System) pipeline landscape.

Peripheral neuropathic pain is a chronic pain state that usually is accompanied by tissue injury. Causes include alcoholism, diabetes, chemotherapy, infections, surgery and multiple sclerosis. Symptoms include burning pain, tingling and numbness. Treatment includes non-steroidal anti-inflammatory drugs, anticonvulsant and antidepressant drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Neuropathic Pain Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral Neuropathic Pain - Overview
    • Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis
  • Peripheral Neuropathic Pain - Therapeutics under Development by Companies
  • Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
  • Peripheral Neuropathic Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peripheral Neuropathic Pain - Products under Development by Companies
  • Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes
  • Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • AnaBios Corporation
    • Chromocell Corporation
    • GW Pharmaceuticals Plc
    • Nektar Therapeutics
    • Phosphagenics Limited
    • Spherium Biomed S.L.
    • Sunovion Pharmaceuticals Inc.
    • Yuhan Corporation
    • Zynerba Pharmaceuticals, Inc.
  • Peripheral Neuropathic Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AXPN-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-8464 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-2230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ECL-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nabiximols - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKTR-171 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxycodone ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-15001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peripheral Neuropathic Pain - Dormant Projects
  • Peripheral Neuropathic Pain - Discontinued Products
  • Peripheral Neuropathic Pain - Product Development Milestones
    • Featured News & Press Releases
      • Oct 12, 2016: FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
      • Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Neuropathic Pain, H2 2016
  • Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H2 2016
  • Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Yuhan Corporation, H2 2016
  • Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peripheral Neuropathic Pain - Dormant Projects, H2 2016
  • Peripheral Neuropathic Pain - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peripheral Neuropathic Pain, H2 2016
  • Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top